<a href="https://www.fiercebiotech.com/medtech/thermo-fisher-scientific-sells-microbiology-biz-1b-european-equity-firm" hreflang="en">Thermo Fisher Scientific sells microbiology business for $1B to European private equity firm</a>
Thermo Fisher Scientific has sold its microbiology business to the European private equity firm Astorg for $1.075 billion, following initial rumors of the sale last year. The unit, which focuses on antimicrobial susceptibility testing and culture media solutions, generated $645 million in revenue in 2025 and will now operate independently under Astorg's management.
For a professional interested in healthtech and biotech, the key insight is that Thermo Fisher Scientific's sale of its microbiology business to Astorg for $1.075 billion presents potential opportunities for growth and enhanced operational performance in microbiology testing, driven by factors like infection complexity and stringent food safety standards. This transaction highlights a strategic shift in the medtech landscape, where private equity firms may increase their investments in specialized diagnostics, potentially opening doors for innovation and partnerships in antimicrobial susceptibility and quality control solutions.